We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Research Institutes Partner to Develop a Global Center for Transformative Nanomedicine

By LabMedica International staff writers
Posted on 25 Oct 2015
Two internationally renowned biomedical research institutions have agreed to collaborate in the establishment of a virtual center to boost development of nanotechnological techniques for diagnosis and treatment of disease.

The Hebrew University of Jerusalem (Israel) and the Cleveland Clinic (OH, USA) announced a five-year commitment to raise at least 15 million USD as initial funding to establish the virtual Center for Transformative Nanomedicine. More...
This center will sponsor interdisciplinary research at the Hebrew University in combination with the Cleveland Clinic’s Department of Biomedical Engineering with the goal of developing nanotechniques that will facilitate therapy and new ways of diagnosing diseases.

Research efforts will encompass a wide range of illnesses including cardiovascular diseases, neurological diseases, and cancer. Investigators involved in the program will endeavor to develop nanomethods for drug transport that will allow delivery of large doses of drugs to be released at a specific site and only to that site, causing fewer side effects than traditional treatments. In addition, they plan to develop inexpensive nanoscale devices to facilitate therapy and diagnosis.

“Our two institutions will leverage resources and begin to combine our scientific knowledge,” said Dr. Menahem Ben-Sasson, president of The Hebrew University of Jerusalem. “These powerful interactions will expedite better medical treatments, more rapid, cost-effective diagnostics, and improved healthcare delivery for people the world over.”

“We are honored to join with Hebrew University to advance the emerging field of nanotechnology,” said Dr. Toby Cosgrove, president and CEO of the Cleveland Clinic. “The new Center for Transformative Nanomedicine will ensure development of novel therapeutics to improve longevity, enhance patient well-being, make medical care more cost-effective, and provide dynamic solutions to global health concerns.”

The initial development stage will be directed by Dr. D. Geoffrey Vince, of the Cleveland Clinic and Dr. Simon Benita of the Hebrew University of Jerusalem.

Related Links:

The Hebrew University of Jerusalem
Cleveland Clinic



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Collection and Transport System
PurSafe Plus®
Gold Member
Hematology Analyzer
Medonic M32B
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.